The rheumatoid arthritis market is estimated to change during the forecast period of 2025-2034, owing to the launch of emerging therapies such as rabeximod (Cyxone), TAS5315 (Taiho Pharmaceutical), AZD1163 and AZD6912 (AstraZeneca), Ocadusertib (Eli Lilly and Company), R-2487 (Rise Therapeutics), MYMD-1 (TNF Pharmaceuticals), and others. Additionally, the rising prevalence and increased healthcare spending will further propel market growth.
LAS VEGAS, Nov. 5, 2025 /PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Rheumatoid Arthritis Market Summary
- The market size for rheumatoid arthritis in the leading markets is expected to grow significantly by 2034.
- The United States accounted for the highest rheumatoid arthritis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
- The total diagnosed prevalent cases of rheumatoid arthritis in the 7MM were assessed to be around ~4.2 million in 2024, and are projected to increase during the study period.
- Leading rheumatoid arthritis companies developing emerging therapies, such as Cyxone, Taiho Pharmaceutical, AstraZeneca, Eli Lilly and Company, Rise Therapeutics, TNF Pharmaceuticals, and others, are developing new therapy for rheumatoid arthritis that can be available in the rheumatoid arthritis market in the coming years.
- The promising rheumatoid arthritis therapies in clinical trials include Rabeximod, TAS5315, AZD1163, AZD6912, Ocadusertib, R-2487, MYMD-1, and others.
Discover the rheumatoid arthritis new treatment @ New Treatments for Rheumatoid Arthritis
Key Factors Driving the Growth of the Rheumatoid Arthritis Market
Rising Rheumatoid Arthritis Disease Prevalence
According to DelveInsight's estimates, the US accounted for around ~1.3 million diagnosed prevalent cases of rheumatoid arthritis in 2024. These cases are further expected to increase by 2034.
Biologic DMARDs and JAK Inhibitors Fuel Future Market Expansion
Current therapies such as biological DMARDs showed promising results in treating rheumatoid arthritis patients, and market penetration is expected to be more in the future and expected to drive market growth. Oral classes such as JAKi are also expected to contribute to the rheumatoid arthritis market growth.
Rising Rheumatoid Arthritis Clinical Trial Activities
Emerging therapies like rabeximod (Cyxone), AZD1163 and AZD6912 (AstraZeneca), ocadusertib (Eli Lilly and Company), R-2487 (Rise Therapeutics), MYMD-1 (TNF Pharmaceuticals), SR-878 (SciRhom), and others are being developed for safe and efficacious treatment options.
Rheumatoid Arthritis Market Analysis
Since the introduction of the first biologic therapy over two decades ago, the treatment landscape for rheumatoid arthritis has undergone a remarkable transformation. The market today is well-established, featuring multiple blockbuster therapies. The approval of Etanercept paved the way for subsequent anti-TNF agents and other classes of rheumatoid arthritis treatments. Biologics, especially anti-TNFs, remain deeply entrenched as the standard of care, and despite the approval of several new therapeutic classes, none have achieved comparable influence or market penetration.
Approved treatments for rheumatoid arthritis include RINVOQ (AbbVie), OLUMIANT (Eli Lilly and Company), KEVZARA (Regeneron/Sanofi), and XELJANZ (Pfizer), among others. Meanwhile, emerging therapies such as rabeximod (Cyxone), AZD1163 and AZD6912 (AstraZeneca), ocadusertib (Eli Lilly and Company), R-2487 (Rise Therapeutics), MYMD-1 (TNF Pharmaceuticals), and SR-878 (SciRhom) are being developed to provide safer and more effective treatment alternatives. Notably, SciRhom has discontinued its Phase I trial for autoimmune disorders in Austria.
The market potential for rheumatoid arthritis therapies remains substantial; six of the world's top 50 bestselling drugs are currently used for rheumatoid arthritis treatment. Major pharmaceutical and biotechnology companies, including AbbVie, Amgen, Roche, Pfizer, Johnson & Johnson, and Bristol Myers Squibb, dominate the space. Many of these industry leaders have fortified their market positions through robust patent protections, effectively limiting biosimilar and generic competition.
To know more about rheumatoid arthritis treatment options, visit @ Approved Rheumatoid Arthritis Drugs
Rheumatoid Arthritis Competitive Landscape
Some of the rheumatoid arthritis drugs in the pipeline include rabeximod (Cyxone), TAS5315 (Taiho Pharmaceutical), AZD1163 and AZD6912 (AstraZeneca), Ocadusertib (Eli Lilly and Company), R-2487 (Rise Therapeutics), MYMD-1 (TNF Pharmaceuticals), and others.
Cyxone's Rabeximod is an orally administered drug with a distinct mechanism of action that selectively targets inflammatory macrophages - white blood cells that play a central role in driving inflammation, tissue destruction, and clinical manifestations of rheumatoid arthritis (RA). It is considered particularly effective during the onset and flare-ups of RA, with strong potential to prevent joint damage and disease progression. The drug is currently in Phase II clinical trials.
Taiho Pharmaceutical's TAS5315 is a novel, highly selective Bruton's tyrosine kinase (BTK) inhibitor. By targeting BTK, the drug may help control inflammation and bone erosion by directly modulating effector cells, such as B cells, macrophages, and osteoclasts, involved in RA. A Phase II clinical trial is underway in Japan to assess the safety and efficacy of TAS5315 in combination with methotrexate in patients with RA who show an inadequate response to methotrexate alone.
AstraZeneca's AZD1163 is a first-in-class bispecific antibody designed to simultaneously inhibit peptidyl arginine deiminases (PADs) 2 and 4 - enzymes responsible for protein citrullination. This process generates autoantigens driving the autoimmune response in RA. By blocking PAD2 and PAD4, AZD1163 seeks to prevent the formation of these autoantigens.
AstraZeneca's AZD6912 is a small interfering RNA (siRNA) therapy targeting human Complement Factor B (CFB), a critical component of the alternative complement pathway. By suppressing hepatic CFB expression, AZD6912 aims to reduce systemic complement activation, thereby mitigating inflammation and tissue damage associated with rheumatoid arthritis.
The anticipated launch of these emerging therapies are poised to transform the rheumatoid arthritis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the rheumatoid arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for rheumatoid arthritis @ Rheumatoid Arthritis Clinical Trials
Recent Developments in the Rheumatoid Arthritis Market
- In October 2025, Lifordi Immunotherapeutics, Inc. shared preclinical findings for its lead candidate, LFD-200, an ADC designed to deliver a potent glucocorticoid (GC) specifically to immune cells. The company also reported that its Phase 1 clinical trial of LFD-200 for Rheumatoid Arthritis has begun, with initial results from healthy participants (HPs) expected by the end of 2025.
- In October 2025, Kymera Therapeutics, Inc. reported new preclinical results for KT-579, a potent and selective oral IRF5 degrader, highlighting its disease-modifying potential across several immuno-inflammatory conditions. The data demonstrate that by specifically targeting and degrading IRF5, a key regulator of immune activity, KT-579 provides a novel oral strategy to inhibit multiple pro-inflammatory pathways involved in disorders like lupus and rheumatoid arthritis.
- In April 2025, Calibr-Skaggs Institute for Innovative Medicines (Scripps Research) received FDA clearance for their IND application to study switchable CAR-T therapy (CLBR001 + SWI019) in autoimmune diseases. The upcoming Phase 1 trial will assess safety and efficacy in patients with myositis, systemic sclerosis, lupus, and rheumatoid arthritis, with plans to potentially expand to other conditions.
What is Rheumatoid Arthritis?
Rheumatoid arthritis is a long-term, inflammatory autoimmune disorder that causes progressive and damaging polyarthritis. It is marked by persistent pain and joint deterioration, typically spreading from the smaller, distal joints to larger, proximal ones. The condition arises when the immune system mistakenly attacks the body's own healthy tissues, though its exact causes remain unclear. RA occurs more frequently in women, who account for roughly 75% of all cases, and it most commonly develops between the ages of 30 and 50.
Rheumatoid Arthritis Epidemiology Segmentation
The rheumatoid arthritis epidemiology section provides insights into the historical and current rheumatoid arthritis patient pool and forecasted trends for the leading markets. In the US, the total prevalent cases of rheumatoid arthritis were nearly ~1.5 million in 2024.
The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Prevalent Cases of Rheumatoid Arthritis
- Total Diagnosed Prevalent Cases of Rheumatoid Arthritis
- Gender-specific Cases of Rheumatoid Arthritis
- Age-specific Cases of Rheumatoid Arthritis
- Severity-specific Cases of Rheumatoid Arthritis
- Patients on Targeted Therapies for Rheumatoid Arthritis
- Line-Wise Treated Cases of Rheumatoid Arthritis
Rheumatoid Arthritis Market Report Metrics | Details |
Study Period | 2020-2034 |
Rheumatoid Arthritis Market Report Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Rheumatoid Arthritis Epidemiology Segmentation | Total Prevalent Cases of Rheumatoid Arthritis, Total Diagnosed Prevalent Cases of Rheumatoid Arthritis, Gender-specific Cases of Rheumatoid Arthritis, Age-specific Cases of Rheumatoid Arthritis, Severity-specific Cases of Rheumatoid Arthritis, Patients on Targeted Therapies for Rheumatoid Arthritis, and Line-Wise Treated Cases of Rheumatoid Arthritis |
Key Rheumatoid Arthritis Companies | Cyxone, Taiho Pharmaceutical, AstraZeneca, Eli Lilly and Company, Rise Therapeutics, TNF Pharmaceuticals, Incyte, UCB, and others |
Key Rheumatoid Arthritis Therapies | Rabeximod, TAS5315, AZD1163, AZD6912, Ocadusertib, R-2487, MYMD-1, RINVOQ, OLUMIANT, CIMZIA, and others |
Scope of the Rheumatoid Arthritis Market Report
- Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies
- Rheumatoid Arthritis Market Dynamics: Key Market Forecast Assumptions of Emerging Rheumatoid Arthritis Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement
Download the report to understand which factors are driving rheumatoid arthritis therapeutics market trends @ Rheumatoid Arthritis Market Trends
Table of Contents
1 | Rheumatoid Arthritis Market Key Insights |
2 | Rheumatoid Arthritis Market Report Introduction |
3 | Executive Summary |
4 | Key Events |
5 | Epidemiology and Market Forecast Flow Methodology |
6 | Rheumatoid Arthritis Market Overview at a Glance |
6.1 | Marketed and Emerging Landscape Analysis (By Phase, RoA, and Molecule Type) |
6.1 | Rheumatoid Arthritis Market Share (%) Distribution by Class in 2024 |
6.2 | Rheumatoid Arthritis Market Share (%) Distribution by Class in 2034 |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Stages of Rheumatoid Arthritis |
7.3 | Types of Rheumatoid Arthritis |
7.3.1 | Seropositive Rheumatoid Arthritis |
7.3.2 | Seronegative Rheumatoid Arthritis |
7.4 | Signs and Symptoms of Rheumatoid Arthritis |
7.5 | Risk Factors and Causes of Rheumatoid Arthritis |
7.6 | Complications of Rheumatoid Arthritis |
7.7 | Pathogenesis of Rheumatoid Arthritis |
7.8 | Diagnosis of Rheumatoid Arthritis |
7.9 | Screening for Rheumatoid Arthritis |
7.10 | Rationale and Impact for Investigations Following The Diagnosis: NICE |
7.11 | Evaluations of Disease Activity in Rheumatoid Arthritis |
7.12 | American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 Classification Criteria for Rheumatoid Arthritis |
8 | Treatment and Management of Rheumatoid Arthritis |
9 | Epidemiology and Patient Population of 7MM |
9.1 | Epidemiology Methodology |
9.2 | Key Findings |
9.3 | Assumptions and Rationale: 7MM |
9.4 | Epidemiology Scenario: 7MM |
9.4.1 | Total Prevalent Cases of Rheumatoid Arthritis in the 7MM |
9.4.2 | Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM |
9.4.3 | Gender-Specific Prevalent Cases of Rheumatoid Arthritis in the 7MM |
9.4.4 | Age-Specific Prevalent Cases of Rheumatoid Arthritis in the 7MM |
9.4.5 | Severity-Specific Prevalent Cases of Rheumatoid Arthritis in the7MM |
9.4.6 | Patients on Targeted Therapies of Rheumatoid Arthritis in the 7MM |
9.4.7 | Line-Wise Treated Cases of Rheumatoid Arthritis in the 7MM |
9.5 | The United States Epidemiology |
9.6 | EU4 and the UK Epidemiology |
9.7 | Japan Epidemiology |
10 | Rheumatoid Arthritis Patient Journey |
11 | Key Endpoints in Rheumatoid Arthritis Clinical Trials |
12 | Marketed Rheumatoid Arthritis Drugs |
12.1 | Key Competitor |
12.2 | OLUMIANT (Barticinib): Eli Lilly and Company/Incyte Corporation |
12.2.1 | Product Description |
12.2.2 | Regulatory Milestone |
12.2.3 | Pivotal Clinical Trial |
12.2.4 | Other Developmental Activities |
12.2.5 | Clinical Development |
12.2.5.1 | Clinical Trials Information |
12.2.6 | Safety and Efficacy |
12.2.7 | Analyst Views |
12.3 | RINVOQ (Upadacitinib): Abbvie |
12.4 | CIMZIA (certolizumab pegol): UCB |
List to be continued in the report… | |
13 | Emerging Rheumatoid Arthritis Drugs |
13.1 | Key Competitors |
13.2 | Rabeximod: Cyxone |
13.2.1 | Product Description |
13.2.2 | Clinical Development |
13.2.3 | Other Developmental Activities |
13.2.4 | Safety and Efficacy |
13.2.5 | Analyst Views |
13.3 | TAS5315: Taiho Pharmaceutical |
List to be continued in the report… | |
14 | Rheumatoid Arthritis Market: 7MM Analysis |
14.1 | Key Findings |
14.2 | Rheumatoid Arthritis Market Outlook |
14.3 | Conjoint Analysis |
14.4 | Key Rheumatoid Arthritis Market Forecast Assumptions |
14.5 | 7MM Rheumatoid Arthritis Market Size |
14.5.1 | Total Market Size of Rheumatoid Arthritis in the 7MM |
14.5.2 | Total Market Size of Rheumatoid Arthritis by Class in the 7MM |
14.5.3 | Total Market Size of Rheumatoid Arthritis by Therapies in the 7MM |
14.6 | United States Rheumatoid Arthritis Market Size |
14.5 | EU4 and the UK Rheumatoid Arthritis Market Size |
14.8 | Japan Rheumatoid Arthritis Market Size |
15 | Rheumatoid Arthritis Market Unmet Needs |
16 | Rheumatoid Arthritis Market SWOT Analysis |
17 | KOL Views on Rheumatoid Arthritis |
18 | Market Access and Reimbursement of Rheumatoid Arthritis |
18.1 | United States |
18.2 | EU4 and the UK |
18.3 | Japan |
18.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
18.5 | Reimbursement Scenario and Key HTA Decisions in Rheumatoid Arthritis |
19 | Bibliography |
20 | Rheumatoid Arthritis Market Report Methodology |
Related Reports
JAK Inhibitors Market
JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast - 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.
Rheumatoid Arthritis Clinical Trial Analysis
Rheumatoid Arthritis Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rheumatoid arthritis companies, including Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc., Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc., Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited., ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc., Candid Therapeutics, Inc., LAPIX Therapeutics, among others.
Juvenile Rheumatoid Arthritis Market
Juvenile Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast - 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including Eli Lilly and Company, Novartis, Sanofi, Regeneron, AbbVie, GeneScience Pharmaceuticals, Cerecor, Bio-Thera Solutions, Mycenax Biotech, Boehringer Ingelheim, among others.
Psoriatic Arthritis Market
Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast - 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PsA companies, including UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rheumatoid-arthritis-market-to-surge-by-2034-as-next-generation-biologics-and-jak-inhibitors-gain-traction--delveinsight-302603568.html
